|
|
Article: Preliminary Results from a Phase IIIb Study Showed Patients With Wet AMD Treated With Lucentis Quarterly Experienced a 16-Letter Benefit Over the Control Group at One Year.
- Article from:
- PR Newswire
- Article date:
- June 2, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Lucentis Groups Showed Initial Increase in Vision from Baseline With Monthly Dosing and Returned to Baseline With Quarterly Treatments
SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire-FirstCall/ -- Genentech, Inc. announced today that a Phase IIIb clinical study of a quarterly dosing regimen of the investigational drug Lucentis(TM) (ranibizumab) for the treatment of wet age-related macular degeneration (AMD) met its primary efficacy endpoint by preventing vision loss as measured by mean change in visual acuity from baseline to month 12. In this study, called PIER, patients receive Lucentis (0.3 mg or 0.5 mg respectively) or sham injections once per month for the ...